TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05419973

Intervention type: OTHER
Intervention: Anthropometric measurement for pregnant women
Description: Weight, length, upper arm circumference

Intervention type: OTHER
Intervention: Anthropometric measurement for infants
Description: birth weight, length, head circumference, nutritional status

Intervention type: OTHER
Intervention: Blood sampling
Description: 3 ml of blood will be taken, 1,5 ml each to measure the complete blood count, and other 1,5 ml to measure ferritin, Fe serum, vitamin D levels, vitamin D receptors, IL-6 and IL-10.

Intervention type: OTHER
Intervention: Blood sampling
Description: 3 ml of blood will be taken, 1,5 ml each to measure the complete blood count, and other 1,5 ml to measure ferritin, Fe serum, vitamin D levels, vitamin D receptors, IL-6 and IL-10.
Study: NCT06166563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: The intervention includes an individualized exercise program in Frequency, Intensity, Time, and Type (FITT).
Study: NCT06485960

Intervention type: OTHER
Intervention: ESDAM validation
Description: * 3\* 24-Hour Dietary Recalls~* Experience Sampling Dietary Assessment Method (mobile application)~* Continuous Blood Glucose Monitoring~* Doubly-labeled water administration~* Blood drawings (Erythrocyte Membrane Fatty Acid composition, Carotenoids)~* Urine sampling (Doubly-labeled water, urinary nitrogen)
Study: NCT05190627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: Loratadine 10mg/day added to rapamycin for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10mg/day added to rapamycin for 12 months
Description: Placebo in the same type of capsule than the experimental drug
Study: NCT05181150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal test
Description: Ingestion of an oral liquid meal (nutridrink), 200 mL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Description: Subcutaneous GIP injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: Subcutaneous GLP-2 injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP + GLP-2
Description: Subcutaneous GIP + GLP-2 injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous saline injection.
Study: NCT06090838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon Pulmonary Angioplasty (BPA)
Description: A balloon pulmonary angioplasty is a minimally invasive intervention procedure to remove blood clots from the pulmonary arteries.
Study: NCT06409429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GX
Description: Patients will receive GX as adjuvant therapy for 6 months. Gemcitabine will be delivered as a 1000 mg/m² intravenous infusion administered on Day 1 and 8 of a 21-day cycle. Capecitabine 2000mg/m²/day will be administered orally for 14 days followed by 7 days' rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX
Description: Patients will receive GX as adjuvant therapy for 6 months. Gemcitabine will be delivered as a 1000 mg/m² intravenous infusion administered on Day 1 and 8 of a 21-day cycle. Capecitabine 2000mg/m²/day will be administered orally for 14 days followed by 7 days' rest.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo 400 mg weekly or placebo 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
Study: NCT05774132

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Subgluteal sciatic nerve block
Description: Patients will be positioned in lateral decubitus and the ultrasound scanning for the sciatic nerve in the subgluteal region will be started between the two bony landmarks (greater trochanter and ischial tuberosity ) using high frequency linear probe then approached via 5 cm block needle under ultrasound guidance after which bupivacaine 0.25% (0.3 ml/kg) will be administered in increments .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided Caudal block
Description: Patients will be positioned in lateral decubitus and their sacral hiatus will be palpated under the scanning of the ultrasound using high frequency linear probe then approached via 5 cm block needle that pierce the sacrococcygeal ligament then will be advanced to caudal canal under ultrasound guidance after which bupivacaine 0.25% (1 ml/kg) will be administered in increments.
Study: NCT05745701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-07081532
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Oral Tablet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Capsule
Study: NCT05694013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roche DPM Module
Description: Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Roche DPM Module
Description: Participants will be trained in the use of the Roche DPM Module, which they will use alongside local SOC support

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab SC
Description: Participants will receive atezolizumab SC for 16 cycles (cycle length = 21 days)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local SOC support
Description: Participants will receive local SOC support

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local SOC support
Description: Participants will receive local SOC support
Study: NCT05478889

Intervention type: PROCEDURE
Intervention: Minimally invasive pancreatoduodenectomy
Description: Whipple's procedure using minimally invasive (laparoscopic/robotic) techniques
Study: NCT05381545

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laser puncture, energy expenditure programming, and low-calories recommended diet programming
Description: This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet .This research group will receive an additional laser puncture (with 3-time per-week design). The following points will be directly contacted by laser, for two minutes: GB34\&28, ST25\&36\&40, SP6, and CV4\&9\&12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: energy expenditure programming and low-calories recommended diet programming
Description: This research group will receive, for 12 weeks, energy expenditure program (Pilates exercise, managed 5 times per week) combined with low calorie diet.
Study: NCT04834544

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DCVAC/OvCa
Description: An active cellular immunotherapy product containing autologous dendritic cells that are generated ex vivo from patient's monocytes and apoptotic tumor cells prepared from tumor cell lines

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06220136

Intervention type: DEVICE
Intervention: TOFscan monitoring
Description: observation and data recording
Study: NCT06462703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-based neurorehabilitation with myReha
Description: The myReha therapy software provides cognitive therapy in the domains attention, executive functions, perception, language, speech, arithmetics, and memory. It automatically creates weekly plans that are individually tailored to a patient's abilities and provides real-time feedback when completing tasks. Intelligent algorithms ensure that the exercises always remain at the optimum level of difficulty.
Study: NCT05116813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipraglurant
Description: Oral 50 mg and 100 mg tablet
Study: NCT05606510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindful exercise
Description: In this study, a modified mindful exercise (ME) program based on mindful standing yoga refers to a type of exercise that aims to harmonize the body and mind through the effect of mindfulness meditation and stretching-awareness to carry on the actual moment through body movement and surroundings without any judgement.

Intervention type: OTHER
Group type: OTHER
Intervention: usual care
Description: Routine medicine and nursing care; as well as hospital-recommended movements (physical stretching).
Study: NCT05834205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric Training
Description: Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 16x2 reps for week 1\&2.~Ankle hops, jump squats, box jump, overhead medicine ball, plyometric push-up, rotational wall with 10x3 reps for week 3\&4.~Ankle hops, jump squats, box jump, depth jump and alternate lunge jump, overhead medicine ball, plyometric push-up, rotational wall with 8x3 reps for week 5\&6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drills
Description: Fast bowling drills (hitting a target, football throw, fast bowler grip) and Ladder Drill
Study: NCT05052021

Intervention type: OTHER
Intervention: Recent or Peri-Operative Covid19 Infection
Description: No intervention will be done. The groups will be differentiated based on whether they had recent or peri-operative Covid19 infection (group 1), or whether they have had no or previous Covid19 infection (Group 2)
Study: NCT05352659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face and online LGBTQ+ training
Description: The intervention consists of Organization-level technical assistance in regard to LGBTQ climate of the organization AND Clinician-level face-to-face virtual workshop LGBTQ competency training, virtual clinical consultations, and links to publicly available LGBTQ training.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On-line training
Description: This study arm receives only links to publicly available on-line LGBTQ training.
Study: NCT05898347

Intervention type: OTHER
Intervention: Active surveillance
Description: Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised.
Study: NCT05665504

Intervention type: DIAGNOSTIC_TEST
Intervention: DetermaRX
Description: A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.

Intervention type: DIAGNOSTIC_TEST
Intervention: DetermaRX
Description: A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.

Intervention type: DIAGNOSTIC_TEST
Intervention: DetermaRX
Description: A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
Study: NCT06168539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emboless
Description: Emboless has the US patent number 8894749 is compared to standard dialysis See also reference Jonsson et al 2023 referred to in the main text.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard dialysis set is used as comparative
Study: NCT05336214

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual CGM initiation service
Description: Primary care practices will refer patients to an external virtual initiation service staffed by clinical pharmacists, diabetes care and education specialists, and physicians. The initiation service will communicate with eligible patients (referred to the virtual initiation service by their provider) to review device options and provide patient education and support on device use for up to 12 months to help initiate use of the device. The initiation service will communicate with a patient's provider about treatment and follow up, but will not make treatment recommendations directly to patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational module on CGM
Description: Primary care practices will complete online educational modules, the American Academy of Family Physicians Transformation in Practice Series on CGM. This series includes education on diabetes; glucose monitoring; evidence behind CGM; CGM implementation tools, strategies, and workflows; billing, reimbursement, and insurance authorization of CGM; and tools and strategies to use CGM for quality improvement in diabetes care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational module on CGM
Description: Primary care practices will complete online educational modules, the American Academy of Family Physicians Transformation in Practice Series on CGM. This series includes education on diabetes; glucose monitoring; evidence behind CGM; CGM implementation tools, strategies, and workflows; billing, reimbursement, and insurance authorization of CGM; and tools and strategies to use CGM for quality improvement in diabetes care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: A practice facilitator will support primary care practices in training team members using the American Academy of Family Physicians Transformation in Practice Series on CGM and in implementation of strategies to support CGM use for patients with diabetes in primary care.
Study: NCT06079372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1850
Description: ALXN1850 will be administered via subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asfotase alfa
Description: Asfotase alfa will be administered via SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asfotase alfa
Description: Asfotase alfa will be administered via SC injection.
Study: NCT06269705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZILRETTA
Description: IA injection of 32 mg ZILRETTA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA-IR
Description: IA injection of 40 mg TCA-IR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IA injection of placebo (normal saline)
Study: NCT06465953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
Study: NCT06239636

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UP421
Description: Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
Study: NCT06549790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03597812
Description: Route of Administration: Oral
Study: NCT06500793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614 capsule
Description: PF614 capsules (25-100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614 capsule
Description: PF614 capsules (25-100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: Nafamostat IR/ER solution/beads (total 1-10 mg)
Study: NCT06258850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol Oral Capsule
Description: One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
Study: NCT06369558

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLYOMETRIC TRAINING
Description: A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRIC TRAINING
Description: A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLASSIC PHYSIOTHERAPY PROGRAM
Description: HOT PACKED ENTEFERANTIAL CURRENT THERAPY AND US THERAPY
Study: NCT06249581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUX-001 40mg once-daily
Description: AUX-001 (extended-release nicorandil) 40mg QD (once-daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUX-001 40mg once-daily
Description: AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
Study: NCT05540145

Intervention type: DRUG
Intervention: SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
Description: Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area \< 1.25m2), bid, D1-8, Q2w 50mg (body surface area \>1.25m2, \<1.5 m2), bid, D1-8, Q2w 60mg (body surface area \>1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100\~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition.
Study: NCT06273761

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management Service (MMS)
Description: Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
Study: NCT05197816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Electrical pulses from implanted generator that adapts to patient activity and/or physiology
Study: NCT06207474

Intervention type: OTHER
Group type: OTHER
Intervention: Video + Chatbot
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Video + Paper
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.

Intervention type: OTHER
Group type: OTHER
Intervention: Paper + Chatbot
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: Paper + Paper
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.